1. Madre LK, Califf RM, Reynolds RF et al (2006) Views from Academia, Industry, and Regulatory Agencies. In: Strom BL, Kimmel SE (eds) Textobook of pharmacoepidemiology. John Wiley & Sons, Chichester, England, pp 63–88
2. Moore TJ, Singh S, Furberg CD (2012) The FDA and new safety warnings. Arch Intern Med 172(1):78–80
3. US Food and Drug Administration (2013) Drug Safety Communications. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm199082.htm . Accessed 24 September 2013
4. European Medicines Agency (2013) Safety monitoring of medicines. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/general/general_content_000456.jsp&mid=WC0b01ac05801ae8fb . Accessed 24 September 2013
5. Wysowski DK, Swartz L (2005) Adverse drug event surveillance and drug withdrawals in the United States, 1969–2002: the importance of reported suspected reactions. Arch Intern Med 165(12):1363–1369